Keyphrases
Epidermal Growth Factor Receptor
100%
Epidermal Growth Factor Receptor Signaling
100%
Soluble Urokinase Plasminogen Activator Receptor (suPAR)
100%
Angiogenesis
100%
Tumor Tissue
75%
Pancreatic Cancer
50%
Targeted Therapy
50%
Vascular Endothelial Growth Factor Receptor 2 (VEGFR2)
50%
Anticancer Therapy
25%
Targeted Cancer Therapy
25%
Blood Levels
25%
Placental Growth Factor (PlGF)
25%
Clinical Trials
25%
Soluble Receptor
25%
Predictive Biomarker
25%
Patient Selection
25%
Immunohistochemistry
25%
Basic Fibroblast Growth Factor (bFGF)
25%
Plasminogen Activator inhibitor-1 (PAI-1)
25%
Cancer Patients
25%
Plasma Parameters
25%
Tumor Subtype
25%
Vascular Endothelial Growth Factor
25%
Tissue Level
25%
Pharmacology, Toxicology and Pharmaceutical Science
Malignant Neoplasm
100%
Epidermal Growth Factor Receptor
100%
Neoplasm
66%
Urokinase Receptor
66%
Vasculotropin Receptor 2
33%
Biological Marker
33%
Immunoassay
16%
Fibroblast Growth Factor 2
16%
Receptor
16%
Vasculotropin A
16%
Plasminogen Activator Inhibitor 1
16%
Clinical Trial
16%
Placental Growth Factor
16%